海马体细胞Ras/Raf/丝裂原活化蛋白激酶变异在耐药性内侧颞叶癫痫中的作用
这项病例对照遗传关联研究分析接受手术的耐药性内侧颞叶癫痫患者海马组织DNA,发现11个致病性体细胞变异富集于海马,其中10个位于PTPN11、SOS1、KRAS、BRAF和NF1基因,预测组成性激活Ras/Raf/MAPK信号通路,对照组未检出。
要点
- 耐药性内侧颞叶癫痫患者海马中检出11个致病性体细胞变异,对照组未检出。
- 10个变异位于PTPN11、SOS1、KRAS、BRAF和NF1,预测激活Ras/Raf/MAPK通路。
- 变异阳性海马组织免疫组化显示Erk1/2磷酸化增加,主要见于胶质细胞。
核心结论
- 海马体细胞变异,特别是激活Ras/Raf/MAPK信号通路的变异,可能参与散发性耐药性内侧颞叶癫痫的发病机制。
- 这些发现可能提供新的遗传机制,并突显该常见癫痫手术适应证的新治疗靶点。
研究设计与样本
- 病例对照遗传关联研究,分析神经外科治疗的耐药性内侧颞叶癫痫患者海马组织DNA与年龄性别匹配的神经正常对照。
- 纳入1988年至2019年在四级癫痫中心治疗的参与者,回顾性收集临床数据。
- 使用全外显子和基因面板测序(每个基因组区域平均测序深度超过500次)识别候选致病性体细胞变异。
- 对部分新变异使用细胞和分子实验进行功能评估。
- 纳入105例耐药性内侧颞叶癫痫患者(53例女性,50.5%,中位年龄32岁,IQR 26-44)和30例神经正常对照(11例女性,36.7%,中位年龄37岁,IQR 18-53)。
主要发现
- 在耐药性内侧颞叶癫痫患者中检出11个致病性体细胞变异,富集于海马相对于未受累颞叶新皮质(中位变异等位基因频率1.92 [IQR 1.5-2.7] vs 0.3 [IQR 0-0.9];P = .01),对照组未检出。
- 11个变异中10个位于PTPN11、SOS1、KRAS、BRAF和NF1,均预测组成性激活Ras/Raf/丝裂原活化蛋白激酶信号通路。
- 变异阳性海马组织的免疫组化研究显示Erk1/2磷酸化增加,表明Ras/Raf/MAPK激活,主要见于胶质细胞。
- 分子实验显示PTPN11变异存在异常的液-液相分离,可能为显性功能获得机制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Mesial temporal lobe epilepsy (MTLE) is the most common focal epilepsy subtype and is often refractory to antiseizure medications. While most patients with MTLE do not have pathogenic germline genetic variants, the contribution of postzygotic (ie, somatic) variants in the brain is unknown. OBJECTIVE: To test the association between pathogenic somatic variants in the hippocampus and MTLE. DESIGN, SETTING, AND PARTICIPANTS: This case-control genetic association study analyzed the DNA derived from hippocampal tissue of neurosurgically treated patients with MTLE and age-matched and sex-matched neurotypical controls. Participants treated at level 4 epilepsy centers were enrolled from 1988 through 2019, and clinical data were collected retrospectively. Whole-exome and gene-panel sequencing (each genomic region sequenced more than 500 times on average) were used to identify candidate pathogenic somatic variants. A subset of novel variants was functionally evaluated using cellular and molecular assays. Patients with nonlesional and lesional (mesial temporal sclerosis, focal cortical dysplasia, and low-grade epilepsy-associated tumors) drug-resistant MTLE who underwent anterior medial temporal lobectomy were eligible. All patients with available frozen tissue and appropriate consents were included. Control brain tissue was obtained from neurotypical donors at brain banks. Data were analyzed from June 2020 to August 2022. EXPOSURES: Drug-resistant MTLE. MAIN OUTCOMES AND MEASURES: Presence and abundance of pathogenic somatic variants in the hippocampus vs the unaffected temporal neocortex. RESULTS: Of 105 included patients with MTLE, 53 (50.5%) were female, and the median (IQR) age was 32 (26-44) years; of 30 neurotypical controls, 11 (36.7%) were female, and the median (IQR) age was 37 (18-53) years. Eleven pathogenic somatic variants enriched in the hippocampus relative to the unaffected temporal neocortex (median [IQR] variant allele frequency, 1.92 [1.5-2.7] vs 0.3 [0-0.9]; P = .01) were detected in patients with MTLE but not in controls. Ten of these variants were in PTPN11, SOS1, KRAS, BRAF, and NF1, all predicted to constitutively activate Ras/Raf/mitogen-activated protein kinase (MAPK) signaling. Immunohistochemical studies of variant-positive hippocampal tissue demonstrated increased Erk1/2 phosphorylation, indicative of Ras/Raf/MAPK activation, predominantly in glial cells. Molecular assays showed abnormal liquid-liquid phase separation for the PTPN11 variants as a possible dominant gain-of-function mechanism. CONCLUSIONS AND RELEVANCE: Hippocampal somatic variants, particularly those activating Ras/Raf/MAPK signaling, may contribute to the pathogenesis of sporadic, drug-resistant MTLE. These findings may provide a novel genetic mechanism and highlight new therapeutic targets for this common indication for epilepsy surgery.
引用
- Khoshkhoo S, Wang Y, Chahine Y, et al. Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy. JAMA Neurol. 2023. PMID: 37126322. doi:10.1001/jamaneurol.2023.0473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。